A phase 2 study of NEO-102 (ensituximab), a novel chimeric monoclonal antibody, in adult patients (pts) with unresecectable metastatic colorectal cancer.
Author: Richard D. Kim, MD
ASCO Annual Meeting, June 3, 2016

Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes
Author: Monica K. Neuman
AACR Annual Meeting, April 18, 2016

A phase II therapeutic, open label, multi-center clinical trial of NPC-1C, a chimeric monoclonal antibody(mAb), in adults with chemotherapy refractory metastatic colorectal cancer (mCRC), initial results.
Author: Richard D. Kim
ASCO GI Symposium, January 21, 2016

A phase I/II multicenter study of the chimeric monoclonal antibody NEO102 (NPC-1C) in adults with refractory pancreatic and Colorectal Cancer
Background: NPC-1C (NEO102) is a novel chimeric monoclonal antibody that recognizes a variant form of Author(s): Muhammad Shaalan Beg
ASCO GI Symposium, January 15, 2015

A multicenter randomized phase II study of NPC-1C (N) in combination with gemcitabine (G) and nab-paclitaxel (A) versus G and A alone in patients with metastatic or locally advanced pancreatic cancer (PC) previously treated with folfirinox (F)
Author(s): Austin G. Duffy
ASCO GI Symposium, January 15, 2015

Precision Biologics

Science & Research Facility
4814 Del Ray Avenue
Bethesda, MD 20814
Investment Inquiries
RJ Childress